Make Informed Investment Decisions with Affordable Access to Experts
Examining therapies in development for Achondroplasia including vosoritide, TransCon CNP, TA-46, and Infigratinib (2 week delayed release to library)Ticker(s): BMRN, ASND, BBIO, Therachon
Name: Dr Gary A. Bellus - MD | PhD
Institution: Geisinger Medical Center
- Director, Clinical Genetics & Genomic Medicine, Geisinger Health System.
- Very familiar with achondroplasia and has taken care of hundreds of patients with this condition over the past 20 years.
- Board-certified and fellowship-trained specialist in clinical genetics. His clinical interests include skeletal dysplasia and genetic skin disorders.
Please describe your clinical practice; roughly how many patients with Achondroplasia do you currently manage?Added By: c_admin
How familiar are you with each vosoritide, TransCon CNP, TA-46, and Infigratinib?Added By: c_admin
Have you referred any patients or had a conversation about referring a patient to one of those clinical trials?Added By: c_admin
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.